Jim Cramer's top 10 things to watch in the stock market Wednesday

SK Hynix reported revenue up more than fourfold and operating profit up more than 600%, with DRAM supply effectively sold out through 2029 and capacity constraints expected through 2030; GE Vernova also cited strong, extended demand for turbines and grid equipment. Visa posted modest fiscal Q4 revenue and earnings beats, while Robinhood fell 6% after a disappointing quarter and Boeing remained under pressure after cutting its long-term free-cash-flow outlook. Markets awaited the Federal Reserve’s rate decision and earnings from Alphabet and Microsoft, with investor focus on AI infrastructure spending and how it will be funded.

Analysis

The most useful signal is a widening AI-infrastructure bottleneck—not a blanket “AI winners” trade. If cloud spending converts into sustained equipment orders, constrained memory can support pricing and utilization at MU and SKHY; higher fab-equipment spending may follow with a lag for LRCX. GEV benefits from power scarcity, but long delivery queues and execution capacity—not demand alone—bound near-term revenue conversion. STX’s long-dated commitments are supportive, yet verify backlog quality and pricing before treating them as equivalent to realized growth. The second-order risk is that cloud capex absorbs cash faster than monetization develops: tonight’s GOOG/MSFT commentary, followed by AMZN, can move both infrastructure suppliers and mega-cap multiples. A capex increase without credible returns could hurt cloud buyers even as suppliers rally.

Near term, the Fed decision and cloud guidance create event risk; avoid adding broad AI exposure before these catalysts. Over 1–3 months, track capex guidance, memory contract pricing, supplier lead times, and cloud free cash flow. Over 6–18 months, capacity additions could ease scarcity and expose cyclical over-ordering. On consumer-facing names, HOOD’s lower take rates are a more durable concern than a single weak quarter if activity remains concentrated in crypto/options; V’s volume resilience is a useful but imperfect consumer check. LLY’s trial result strengthens its pipeline narrative, but clinical, regulatory, and launch execution remain between data and revenue; do not equate a head-to-head result with near-term sales displacement at NVO.

Contrarian: the market may be extrapolating AI scarcity too far into 2029–32. Conversely, BA’s cash-flow reset may be underappreciated if delivery and production recovery take longer than investors expect. Treat both as catalyst-dependent, not simple valuation calls.

Key Decisions for Investors

• Prefer a staged long MU / smaller long LRCX exposure on a post-Fed or post-cloud-earnings pullback, rather than chasing the morning strength. Thesis: constrained memory supports pricing, with equipment orders a later read-through. Reassess if memory pricing or order commentary rolls over, or if cloud capex disappoints.
• Keep GEV on a pullback watchlist, not a market-order chase. Confirm that backlog converts into deliveries and margins; cancellations, slippage, or evidence that data-center power demand is being deferred would invalidate the demand thesis.
• Avoid buying HOOD solely on the decline. Watch crypto activity, options volumes, and take-rate trends over the next quarter; persistent take-rate compression alongside weak engagement would argue for further estimate risk. A broad crypto rebound alone may not repair unit economics.
• Do not initiate an LLY-versus-NVO pair on this trial headline alone. Revisit after full trial details, safety/tolerability data, and FDA timing are clearer; the thesis weakens if the efficacy advantage does not translate into differentiated prescribing or access.
• For BA, wait for evidence on production, deliveries, and cash conversion before treating the reset as a floor. For UPS/FDX, use FDX and FDXF results as the near-term test of whether yield-focused mix improvement offsets volume and network costs; no pair trade until guidance is comparable.